Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa - Maiza, J C; Vezzosi, D; Matta, M (Clin Endocrinol (Oxf), 2007)
et al.